FTC Continues to Issue CBD Warning Letters

Earlier this week the Federal Trade Commission (FTC) sent out warning letters to three unnamed companies that sell cannabidiol (CBD) oils, tinctures, edibles and other products which claim to treat pain and chronic illnesses or cure diseases.

In its letters to the companies, the FTC warned that it is illegal to advertise that a CBD product can prevent, treat or cure illnesses without reliable scientific evidence to support such claims.

Reportedly, one company claimed that CBD has been clinically proven to treat cancer, Alzheimer’s disease multiple sclerosis, fibromyalgia, nicotine addition and colitis and stated that it had participated in thousands of hours of research with Harvard researchers, while another promoted its CBD gummy products as being highly effective at treating most major degenerative diseases including arthritis, heart disease, fibromyalgia, cancer, asthma and a wide spectrum of autoimmune disorders.’

In its letters, the FTC asked each company to review all claims made for their products, including consumer testimonials to ensure each claim is supported by competent and reliable scientific evidence. Additionally, the FTC warned each company that selling CBD products without substantiation could violate the FTC Act and result in legal action.